| Overview |
| bsm-51201M |
| PODXL (2C4) Monoclonal Antibody |
| WB, IHC-P, IF |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This PODXL antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 410-439 amino acids from the C-terminal region of human PODXL. |
| Monoclonal |
| 2C4 |
| IgG1 |
| 0.5ug/ul |
| Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 5420 |
| O00592 |
| PC; PCLP; Gp200; PCLP-1; Podocalyxin; GCTM-2 antigen; Podocalyxin-like protein 1; PODXL; PCLP1 |
| Involved in the regulation of both adhesion and cell morphology and cancer progression. Function as an anti-adhesive molecule that maintains an open filtration pathway between neighboring foot processes in the podocyte by charge repulsion. Acts as a pro-adhesive molecule, enhancing the adherence of cells to immobilized ligands, increasing the rate of migration and cell-cell contacts in an integrin-dependent manner. Induces the formation of apical actin-dependent microvilli. Involved in the formation of a preapical plasma membrane subdomain to set up inital epithelial polarization and the apical lumen formation during renal tubulogenesis. Plays a role in cancer development and aggressiveness by inducing cell migration and invasion through its interaction with the actin-binding protein EZR. Affects EZR-dependent signaling events, leading to increased activities of the MAPK and PI3K pathways in cancer cells. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF |
|
Powered by Bioz